Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Vitamin D inhibits the occurrence of experimental cerebral malaria in mice by suppressing the host inflammatory response.

He X, Yan J, Zhu X, Wang Q, Pang W, Qi Z, Wang M, Luo E, Parker DM, Cantorna MT, Cui L, Cao Y.

J Immunol. 2014 Aug 1;193(3):1314-23. doi: 10.4049/jimmunol.1400089. Epub 2014 Jun 25.

2.

Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA.

Palomo J, Fauconnier M, Coquard L, Gilles M, Meme S, Szeremeta F, Fick L, Franetich JF, Jacobs M, Togbe D, Beloeil JC, Mazier D, Ryffel B, Quesniaux VF.

Eur J Immunol. 2013 Oct;43(10):2683-95. doi: 10.1002/eji.201343327. Epub 2013 Jul 19.

3.

Critical role of IL-33 receptor ST2 in experimental cerebral malaria development.

Palomo J, Reverchon F, Piotet J, Besnard AG, Couturier-Maillard A, Maillet I, Tefit M, Erard F, Mazier D, Ryffel B, Quesniaux VF.

Eur J Immunol. 2015 May;45(5):1354-65. doi: 10.1002/eji.201445206. Epub 2015 Mar 20.

4.

Pre-existing Schistosoma japonicum infection alters the immune response to Plasmodium berghei infection in C57BL/6 mice.

Wang ML, Cao YM, Luo EJ, Zhang Y, Guo YJ.

Malar J. 2013 Sep 14;12:322. doi: 10.1186/1475-2875-12-322.

5.

IL-12Rβ2 is essential for the development of experimental cerebral malaria.

Fauconnier M, Palomo J, Bourigault ML, Meme S, Szeremeta F, Beloeil JC, Danneels A, Charron S, Rihet P, Ryffel B, Quesniaux VF.

J Immunol. 2012 Feb 15;188(4):1905-14. doi: 10.4049/jimmunol.1101978. Epub 2012 Jan 11.

6.

Induction of pro-inflammatory mediators in Plasmodium berghei infected BALB/c mice breaks blood-brain-barrier and leads to cerebral malaria in an IL-12 dependent manner.

Schmidt KE, Schumak B, Specht S, Dubben B, Limmer A, Hoerauf A.

Microbes Infect. 2011 Sep;13(10):828-36. doi: 10.1016/j.micinf.2011.04.006. Epub 2011 May 12.

PMID:
21609776
7.

IFN-γ-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain.

Villegas-Mendez A, Greig R, Shaw TN, de Souza JB, Gwyer Findlay E, Stumhofer JS, Hafalla JC, Blount DG, Hunter CA, Riley EM, Couper KN.

J Immunol. 2012 Jul 15;189(2):968-79. doi: 10.4049/jimmunol.1200688. Epub 2012 Jun 20.

8.

Phenylhydrazine administration accelerates the development of experimental cerebral malaria.

Zhu X, Liu J, Feng Y, Pang W, Qi Z, Jiang Y, Shang H, Cao Y.

Exp Parasitol. 2015 Sep;156:1-11. doi: 10.1016/j.exppara.2015.05.011. Epub 2015 May 21.

PMID:
26005191
9.

Protein kinase C θ deficiency increases resistance of C57BL/6J mice to Plasmodium berghei infection-induced cerebral malaria.

Ohayon A, Golenser J, Sinay R, Tamir A, Altman A, Pollack Y, Isakov N.

Infect Immun. 2010 Oct;78(10):4195-205. doi: 10.1128/IAI.00465-10. Epub 2010 Jul 26.

10.

Toxoplasma gondii upregulates interleukin-12 to prevent Plasmodium berghei-induced experimental cerebral malaria.

Settles EW, Moser LA, Harris TH, Knoll LJ.

Infect Immun. 2014 Mar;82(3):1343-53. doi: 10.1128/IAI.01259-13. Epub 2014 Jan 6.

11.

Differential role of T regulatory and Th17 in Swiss mice infected with Plasmodium berghei ANKA and Plasmodium yoelii.

Keswani T, Bhattacharyya A.

Exp Parasitol. 2014 Jun;141:82-92. doi: 10.1016/j.exppara.2014.03.003. Epub 2014 Mar 24.

PMID:
24675415
12.

L-arginine exacerbates experimental cerebral malaria by enhancing pro-inflammatory responses.

Xu H, Feng Y, Chen G, Zhu X, Pang W, Du Y, Wang Q, Qi Z, Cao Y.

Tohoku J Exp Med. 2015;236(1):21-31. doi: 10.1620/tjem.236.21.

13.

IRGM3 contributes to immunopathology and is required for differentiation of antigen-specific effector CD8+ T cells in experimental cerebral malaria.

Guo J, McQuillan JA, Yau B, Tullo GS, Long CA, Bertolino P, Roediger B, Weninger W, Taylor GA, Hunt NH, Ball HJ, Mitchell AJ.

Infect Immun. 2015 Apr;83(4):1406-17. doi: 10.1128/IAI.02701-14. Epub 2015 Feb 2.

14.

The transcription factor T-bet regulates parasitemia and promotes pathogenesis during Plasmodium berghei ANKA murine malaria.

Oakley MS, Sahu BR, Lotspeich-Cole L, Solanki NR, Majam V, Pham PT, Banerjee R, Kozakai Y, Derrick SC, Kumar S, Morris SL.

J Immunol. 2013 Nov 1;191(9):4699-708. doi: 10.4049/jimmunol.1300396. Epub 2013 Sep 27.

15.

Involvement of IFN-gamma receptor-medicated signaling in pathology and anti-malarial immunity induced by Plasmodium berghei infection.

Amani V, Vigário AM, Belnoue E, Marussig M, Fonseca L, Mazier D, Rénia L.

Eur J Immunol. 2000 Jun;30(6):1646-55.

16.

Prevention of experimental cerebral malaria by Flt3 ligand during infection with Plasmodium berghei ANKA.

Tamura T, Kimura K, Yuda M, Yui K.

Infect Immun. 2011 Oct;79(10):3947-56. doi: 10.1128/IAI.01337-10. Epub 2011 Aug 1.

17.

The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology.

Hafalla JC, Claser C, Couper KN, Grau GE, Renia L, de Souza JB, Riley EM.

PLoS Pathog. 2012 Feb;8(2):e1002504. doi: 10.1371/journal.ppat.1002504. Epub 2012 Feb 2.

18.

Parasite densities modulate susceptibility of mice to cerebral malaria during co-infection with Schistosoma japonicum and Plasmodium berghei.

Wang ML, Feng YH, Pang W, Qi ZM, Zhang Y, Guo YJ, Luo EJ, Cao YM.

Malar J. 2014 Mar 26;13:116. doi: 10.1186/1475-2875-13-116.

19.

Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice.

Vigário AM, Belnoue E, Grüner AC, Mauduit M, Kayibanda M, Deschemin JC, Marussig M, Snounou G, Mazier D, Gresser I, Rénia L.

J Immunol. 2007 May 15;178(10):6416-25.

20.

Interferon-gamma is essential for the development of cerebral malaria.

Rudin W, Favre N, Bordmann G, Ryffel B.

Eur J Immunol. 1997 Apr;27(4):810-5. Retraction in: Eur J Immunol. 1998 Oct;28(10):3398.

PMID:
9130629
Items per page

Supplemental Content

Write to the Help Desk